Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition

Yao Yao, Woojun D Park, Eugenio Morelli, MD, Mehmet Kemal Samur, PhD, Nicholas P Kwiatkowski, PhD, Yan Xu, MD, Chandraditya Chakraborty, PhD, Behnam Nabet, PhD, Marta Chesi, PhD, Herve Avet-Loiseau, Nathaniel Gray, Richard A. Young, PhD, Kenneth Anderson, MD, Charles Y Lin, PhD, Nikhil C. Munshi, MD, Mariateresa Fulciniti, PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-142592

Published: 2020

Journal Articles

Myeloma Cells Addicted to Glutamine for Biomass Production Are Sensitive to Lenalidomide

Sinto Chirackal, PhD, Esteban Braggio, PhD, Rahman Atiqur, PhD, Gregory J Ahmann, BS, Yuan Xiao Zhu, PhD, A. Keith Stewart, MB, ChB, Marta Chesi, PhD, P. Leif Bergsagel, MD, Rafael Fonseca, MD

Blood (2019) 134 (Supplement_1): 4410.

https://doi.org/10.1182/blood-2019-124967

Published: 2019

Journal Articles

Altered Iron Metabolism Is a New Targetable Hallmark for Multiple Myeloma

Can Li, MD, Xuelian Tan, Qierra Brockman, BA, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Marta Chesi, PhD, P. Leif Bergsagel, MD, Fangping Chen, MD PhD, Ivana Frech, DSc, PhD MBA, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 3059.

https://doi.org/10.1182/blood-2019-123473

Published: 2019

Journal Articles

Reconstructing the Clonal and Mutational Architecture of Myeloma through Avian Leukosis Virus (ALV)-Mediated Genome Editing

Zachary Morrow, BS, Alexander Cicala, Evan Flietner, BS, Athanasios Papadas, MD, Adam Pagenkopf, BS, Zhi Wen, PhD, Adhithi Rajagopalan, BS, Poulikos Poulikakos, PhD, Natalie Scott Callander, MD, Marta Chesi, PhD, P. Leif Bergsagel, MD, Jing Zhang, PhD, Fotios Asimakopoulos, PhD MBBChir,

Blood (2018) 132 (Supplement 1): 4480.

https://doi.org/10.1182/blood-2018-99-115288

Published: 2018

Journal Articles

A Single-Cell Transcriptional Analysis of Tumour Cells and the Immune Microenvironment during Disease Evolution in a Transgenic Mouse Model of Myeloma

Danielle C Croucher, MSc, Marta Chesi, PhD, Zhihua Li, Victoria Marie Garbitt, BS, Meaghen E Sharik, BS, Daniel Waller, PhD, Michael Sebag, MD PhD, P. Leif Bergsagel, MD, Trevor J. Pugh, PhD, Suzanne Trudel, MD FRCP(C)

Blood (2018) 132 (Supplement 1): 56.

https://doi.org/10.1182/blood-2018-99-118691

Published: 2018

Journal Articles

Mice Expressing MYC and Nras Q61R in Germinal Center B Cells Develop Highly Aggressive Multiple Myeloma

Adhithi Rajagopalan, BS, Zhi Wen, PhD, Quinlan Furumo, Erik A. Ranheim, MD PhD, Remington Finn, Evan Flietner, BS, Grant Yun, Yun Zhou, MS, Mei Yu, PhD, Natalie Scott Callander, MD, Marta Chesi, PhD, P. Leif Bergsagel, MD, Robert Burns, PhD, Demin Wang, PhD, Fotios Asimakopoulos, PhDMBBChir,, Jing Zhang, PhD

Blood (2018) 132 (Supplement 1): 1006.

https://doi.org/10.1182/blood-2018-99-116757

Published: 2018

Journal Articles

Donor T Cells Maintain Myeloma-Immune Equilibrium after Autologous Stem Cell Transplantation and Concurrent Immunotherapy Promotes Cure

Simone A Minnie, David Smith, Kate H Gartlan, PhD, Thomas S Watkins, Kate A Markey, PhD MBBS, Camille Guillerey, PhD, Rachel D Kuns, BSc, Kelly R Locke, Antiopi Varelias, PhD, Ping Zhang, Nicholas Huntington, PhD, Marta Chesi, PhD, John J Miles, PhD, Mark J Smyth, PhD, Slavica Vuckovic, PhD, Geoffrey R Hill, MD PhD

Blood (2018) 132 (Supplement 1): 2031.

https://doi.org/10.1182/blood-2018-99-118058

Published: 2018

Journal Articles

PIKfyve Inhibitors for the Treatment of Multiple Myeloma

Cecilia Bonolo De Campos, PhD, Yuan Xiao Zhu, PhD, Chang-Xin Shi, PhD, Laura Ann Bruins, BS, Joachim L Petit, PhD, Alysia N Polito, BS, Meaghen E Sharik, BS, Caleb K Stein, MS, Gregory J Ahmann, BS, Ilsel D Lopez Armenta, BS, Nikolai Sepetov, PhD, Sergei Romanov, PhD, P. Leif Bergsagel, MD, Marta Chesi, PhD, Nathalie Meurice, PhD, A. Keith Stewart, MBChB, MBA

Blood (2017) 130 (Supplement 1): 4423.

https://doi.org/10.1182/blood.V130.Suppl_1.4423.4423

Published: 2017

Journal Articles

Translational Research of PT-112, a Clinical Agent in Advanced Phase I Development: Evident Bone Tropism, Synergy In Vitro with Bortezomib and Lenalidomide , and Potent Efficacy in the Vk*MYC Mouse Model of Multiple Myeloma

Tyler D Ames, PhD, Meaghen E Sharik, BS, Gulam M Rather, PhD, Guillaume Hochart, MPhil, David Bonnel, PhD, Stefan Linehan, Jonathan Stauber, PhD, Richard A Wing, PhD, Jose J Jimeno, MD, Daniel Medina, PhD, Joseph R Bertino, MD, Marta Chesi, PhD, P. Leif Bergsagel, MD

Blood (2017) 130 (Supplement 1): 1797.

https://doi.org/10.1182/blood.V130.Suppl_1.1797.1797

Published: 2017

Journal Articles

Using Single Cell RNA Sequencing to Characterize Cell-Type Specific Gene Expression in a Mouse Model of Multiple Myeloma Treated with the cIAP Antagonist LCL161

Nicholas Banovich, PhD, Martin Boateng, BS, P. Leif Bergsagel, MD, Marta Chesi, PhD, Jonathan J. Keats, PhD

Blood (2017) 130 (Supplement 1): 1772.

https://doi.org/10.1182/blood.V130.Suppl_1.1772.1772

Published: 2017

Journal Articles

Inhibition of the Epigenetic Modifier EZH2 Upregulates Cell Cycle Control Genes to Inhibit Myeloma Cell Growth and Overcome High-Risk Disease Features

Charlotte Pawlyn, MB BChir, Michael Bright, PhD, Amy Buros, PhD, Caleb K. Stein, MS, Zoe Walters, PhD, Lauren Aronson, PhD, Fabio Mirabella, PhD, Martin F Kaiser, MD, John R Jones, MD, Brian A Walker, PhD, Graham H Jackson, MD PhD, Paul Clarke, PhD, Leif Bergsagel, MD, Paul Workman, PhD, Marta Chesi, PhD, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2016) 128 (22): 3289.

https://doi.org/10.1182/blood.V128.22.3289.3289

Published: 2016

Journal Articles

Complementary Activation of Ccnd, MYC, RAS and NFkB By Mutations in Multiple Myeloma

Kristine Misund, PhD, Niamh Keane, MD, Yan W Asmann, PhD, Scott Van Wier, Daniel Riggs, PhD, Gregory Ahmann, Marta Chesi, PhD, K. Martin Körtum, MD, Rafael Fonseca, MD, A. Keith Stewart, MD, Esteban Braggio, PhD, P. Leif Bergsagel, MD

Blood (2016) 128 (22): 355.

https://doi.org/10.1182/blood.V128.22.355.355

Published: 2016

Journal Articles

Lenalidomide Inhibits Thioredoxin Reductase (TrxR) in Multiple Myeloma (MM) Cells but Direct Inhibition of Trxr and Thioredoxin (Trx) Can Bypass Requirement of Cereblon (CRBN)

Sinto Sebastian Chirackal, PhD, Esteban Braggio, PhD, Yuan Xiao Zhu, PhD, Chang-Xin Shi, PhD, Scott Van Wier, Gregory Ahmann, Veronica Gonzalez-Calle, MD, Marta Chesi, PhD, Leif Bergsagel, MD, Keith Stewart, M.B., Ch.B., Rafael Fonseca, MD

Blood (2016) 128 (22): 4482.

https://doi.org/10.1182/blood.V128.22.4482.4482

Published: 2016

Journal Articles

Immunomodulatory Drugs Inhibit H 2 O 2 Decomposition in Multiple Myeloma Cells and Its Mediated Cytotoxicity Is Determined By Cellular Antioxidative Capacity

Sinto Sebastian Chirackal, PhD, Yuan Xiao Zhu, PhD, Esteban Braggio, PhD, Chang-Xin Shi, PhD, Sonali Panchabhai, MBBS, Gregory Ahmann, BS, Scott A. Van Wier, BS, Marta Chesi, PhD, Leif Bergsagel, MD PhD, Keith Stewart, MD, Rafael Fonseca, MD

Blood (2015) 126 (23): 2475.

https://doi.org/10.1182/blood.V126.23.2475.2475

Published: 2015

Journal Articles

Characterization of the Role of Regulatory T Cells (Tregs) in Inducing Progression of Multiple Myeloma

Yawara Kawano, MDPhD, Michele Moschetta, MD, Katsutoshi Kokubun, PhD, Pavlo Lukyanchykov, MD, Esilida Sula Karreci, MD, Salomon Manier, MD, Shokichi Tsukamoto, MD PhD, Satoshi Takagi, PhD, Jiantao Shi, Michaela R. Reagan, PhD, Daisy Huynh, BS, MS, Antonio Sacco, BS, David M. Dorfman, MD PhD, Marta Chesi, PhD, Peter Leif Bergsagel, MD PhD, Aldo M Roccaro, MD PhD, Jamil Azzi, MD, Irene M. Ghobrial, MD

Blood (2015) 126 (23): 502.

https://doi.org/10.1182/blood.V126.23.502.502

Published: 2015

Journal Articles

UCHL1 Is a Biomarker of Aggressive Multiple Myeloma Required for Disease Progression

Sajjad Hussain, PhD, Tibor Bedekovics, PhD, Marta Chesi, PhD, Leif Bergsagel, MD PhD, Paul J. Galardy, MD

Blood (2015) 126 (23): 2980.

https://doi.org/10.1182/blood.V126.23.2980.2980

Published: 2015

Journal Articles

Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial

P. Leif Bergsagel, MD, Martha Q. Lacy, MD, David Dingli, MD PhD, Shaji K. Kumar, MD, Sikander Ailawadhi, MD, Angela Dispenzieri, MD, Francis Buadi, MD, Morie A. Gertz, MD, A. Keith Stewart, MD, Craig B. Reeder, MD, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, Yi Lin, MD PhD, Asher Alban Chanan-Khan, MD, Marta Chesi, PhD

Blood (2015) 126 (23): 3039.

https://doi.org/10.1182/blood.V126.23.3039.3039

Published: 2015

Journal Articles

Pre-Clinical Activity of the Novel, First-in-Class p97 Inhibitor, CB-5083, in Multiple Myeloma

Blood (2014) 124 (21): 4701.

https://doi.org/10.1182/blood.V124.21.4701.4701

Published: 2014

Journal Articles

Early Trafficking of Bone Marrow Derived-Endothelial Progenitor Cells Promotes Multiple Myeloma Progression

Michele Moschetta, MD, Yuji Mishima, PhD, Yawara Kawano, MD PhD, Yosra Aljawai, MS, Bruno Paiva, PhD, Luis Palomera, MD, Arianna Calcinotto, Unitt L. Christine, BSc, Ilyas Sahin, MD, Antonio Sacco, BS, Siobhan Glavey, MD, Michaela R. Reagan, PhD, Salomon Manier, MD, Peter Leif Bergsagel, MD PhD, Marta Chesi, PhD, Matteo Bellone, MD, Aldo M Roccaro, MD PhD, Irene M. Ghobrial, MD

Blood (2014) 124 (21): 4719.

https://doi.org/10.1182/blood.V124.21.4719.4719

Published: 2014

Journal Articles

Identification of Novel Therapeutic Targets in the Clinically Predictive Vk*MYC Mouse Model of Multiple Myeloma

Marta Chesi, PhD, Victoria Garbitt, P. Leif Bergsagel, MD

Blood (2014) 124 (21): 415.

https://doi.org/10.1182/blood.V124.21.415.415

Published: 2014

NARROW

Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition

Myeloma Cells Addicted to Glutamine for Biomass Production Are Sensitive to Lenalidomide

Altered Iron Metabolism Is a New Targetable Hallmark for Multiple Myeloma

Reconstructing the Clonal and Mutational Architecture of Myeloma through Avian Leukosis Virus (ALV)-Mediated Genome Editing

A Single-Cell Transcriptional Analysis of Tumour Cells and the Immune Microenvironment during Disease Evolution in a Transgenic Mouse Model of Myeloma

Mice Expressing MYC and Nras Q61R in Germinal Center B Cells Develop Highly Aggressive Multiple Myeloma

Donor T Cells Maintain Myeloma-Immune Equilibrium after Autologous Stem Cell Transplantation and Concurrent Immunotherapy Promotes Cure

PIKfyve Inhibitors for the Treatment of Multiple Myeloma

Translational Research of PT-112, a Clinical Agent in Advanced Phase I Development: Evident Bone Tropism, Synergy In Vitro with Bortezomib and Lenalidomide , and Potent Efficacy in the Vk*MYC Mouse Model of Multiple Myeloma

Using Single Cell RNA Sequencing to Characterize Cell-Type Specific Gene Expression in a Mouse Model of Multiple Myeloma Treated with the cIAP Antagonist LCL161

Inhibition of the Epigenetic Modifier EZH2 Upregulates Cell Cycle Control Genes to Inhibit Myeloma Cell Growth and Overcome High-Risk Disease Features

Complementary Activation of Ccnd, MYC, RAS and NFkB By Mutations in Multiple Myeloma

Lenalidomide Inhibits Thioredoxin Reductase (TrxR) in Multiple Myeloma (MM) Cells but Direct Inhibition of Trxr and Thioredoxin (Trx) Can Bypass Requirement of Cereblon (CRBN)

Immunomodulatory Drugs Inhibit H 2 O 2 Decomposition in Multiple Myeloma Cells and Its Mediated Cytotoxicity Is Determined By Cellular Antioxidative Capacity

Characterization of the Role of Regulatory T Cells (Tregs) in Inducing Progression of Multiple Myeloma

UCHL1 Is a Biomarker of Aggressive Multiple Myeloma Required for Disease Progression

Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial

Pre-Clinical Activity of the Novel, First-in-Class p97 Inhibitor, CB-5083, in Multiple Myeloma

Early Trafficking of Bone Marrow Derived-Endothelial Progenitor Cells Promotes Multiple Myeloma Progression

Identification of Novel Therapeutic Targets in the Clinically Predictive Vk*MYC Mouse Model of Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only